head and neck cancer
Cel-Sci, FDA Agree on Biomarker-Defined Confirmatory Study for Multikine
The trial, slated to begin next year, will enroll 200 patients with newly diagnosed, advanced head and neck cancer and low PD-L1 expression.
Akiram Therapeutics' CD44v6-Targeted Radiopharmaceutical to Enter Phase I Trials in Sweden
Swedish regulators cleared a clinical trial application, allowing Karolinska University Hospital investigators to begin studying 177Lu-AKIR001.
Cofactor Genomics Immunotherapy Response Test Nabs Medicare Coverage
The assay evaluates a patient's tumor immune profile against Cofactor's high-dimensional RNA-based Health Expression Models to predict a patient's therapy response.
TheraVectys Launches Phase I/IIa Trial of HPV-Targeted Vaccine in Cervical, Oropharyngeal Cancers
The trial will include patients with newly diagnosed, treatment-naïve cancers as well as those with recurrent or metastatic disease.
A study presented at the ESMO Congress shed light on an ADC directed against an immune checkpoint in PD-L1-expressing solid cancers.